In global pharmaceutical companies, supply-chain product
proliferation and organizational complexity are a mutually reinforcing
Gordian knot that manufacturing and commercial leaders struggle to cut.
this article, you'll learn how one global pharmaceutical company
overcame deep-set resistance, cultural legacies and organizational
barriers in order to systematically remove low-value products from its
portfolio. With coordinated demands for results, new forms of
collaboration, and expectations of rapid progress, leaders transformed
the product portfolio into a high-performing one better suited to
compete profitably in today's pharmaceutical environment.
Pharma, May-June 2012